JP2013508382A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508382A5
JP2013508382A5 JP2012535319A JP2012535319A JP2013508382A5 JP 2013508382 A5 JP2013508382 A5 JP 2013508382A5 JP 2012535319 A JP2012535319 A JP 2012535319A JP 2012535319 A JP2012535319 A JP 2012535319A JP 2013508382 A5 JP2013508382 A5 JP 2013508382A5
Authority
JP
Japan
Prior art keywords
ethyl
methyl
pharmaceutically acceptable
dihydropyrido
tetrahydropyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508382A (ja
JP5581390B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/053295 external-priority patent/WO2011050016A1/en
Publication of JP2013508382A publication Critical patent/JP2013508382A/ja
Publication of JP2013508382A5 publication Critical patent/JP2013508382A5/ja
Application granted granted Critical
Publication of JP5581390B2 publication Critical patent/JP5581390B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012535319A 2009-10-23 2010-10-20 Akt阻害剤 Expired - Fee Related JP5581390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25430809P 2009-10-23 2009-10-23
US61/254,308 2009-10-23
PCT/US2010/053295 WO2011050016A1 (en) 2009-10-23 2010-10-20 Akt inhibitors

Publications (3)

Publication Number Publication Date
JP2013508382A JP2013508382A (ja) 2013-03-07
JP2013508382A5 true JP2013508382A5 (https=) 2013-06-06
JP5581390B2 JP5581390B2 (ja) 2014-08-27

Family

ID=43467018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535319A Expired - Fee Related JP5581390B2 (ja) 2009-10-23 2010-10-20 Akt阻害剤

Country Status (12)

Country Link
US (1) US8436002B2 (https=)
EP (1) EP2491032B1 (https=)
JP (1) JP5581390B2 (https=)
KR (1) KR101398268B1 (https=)
CN (1) CN102574852B (https=)
AU (1) AU2010310786B2 (https=)
BR (1) BR112012011328A2 (https=)
CA (1) CA2778291C (https=)
EA (1) EA020151B1 (https=)
ES (1) ES2465094T3 (https=)
MX (1) MX2012004780A (https=)
WO (1) WO2011050016A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180948T1 (hr) 2012-05-17 2018-08-10 Genentech, Inc. Postupak za proizvodnju aminokiselinskih spojeva
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
US9416110B2 (en) 2012-05-17 2016-08-16 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
KR102678074B1 (ko) 2012-05-17 2024-06-26 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
EP2920154B1 (en) * 2012-11-16 2017-10-11 Merck Patent GmbH Novel imidazol-piperidinyl derivatives as modulators of kinase activity
AR095202A1 (es) * 2013-03-11 2015-09-30 Merck Patent Gmbh Heterociclos como moduladores de la actividad quinasa
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
GB201401198D0 (en) * 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
EP3476392A1 (en) 2014-02-28 2019-05-01 Merck Sharp & Dohme Corp. Method for treating cancer
PT3459953T (pt) * 2016-05-20 2021-07-29 Taiho Pharmaceutical Co Ltd Novo derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona
AU2020214258B2 (en) * 2019-01-29 2025-08-28 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. AKT inhibitor
JP2023525757A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Akt3モジュレーター
CN115485276B (zh) * 2020-05-15 2024-05-31 南京正大天晴制药有限公司 氘代akt激酶抑制剂
US20230321108A1 (en) * 2020-07-22 2023-10-12 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Unit dosage composition of akt inhibitor
WO2022017448A1 (zh) * 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
US20230286979A1 (en) * 2020-07-22 2023-09-14 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7767687B2 (en) 2004-12-13 2010-08-03 Biogen Idec Ma Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
JP5274842B2 (ja) * 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
US7930013B2 (en) 2005-06-29 2011-04-19 Compumedics Limited Sensor assembly with conductive bridge
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
JP2009534456A (ja) * 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) * 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme

Similar Documents

Publication Publication Date Title
JP2013508382A5 (https=)
JP2010540509A5 (https=)
SG11202111918PA (en) Substituted cycloalkyls as modulators of the integrated stress pathway
ES2638850T3 (es) Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos
JP2008513498A5 (https=)
JP2019077725A5 (https=)
JP2008535902A5 (https=)
JP2013510124A5 (https=)
ME01462B (me) Vinilindazolilna jedinjenja"
JP2006524660A5 (https=)
WO2017193030A1 (en) Modulators of the integrated stress pathway
JP2019510798A5 (https=)
JP2011509309A5 (https=)
JP2009532452A5 (https=)
JP2011507896A5 (https=)
JP2011500758A5 (https=)
JP2010241830A5 (https=)
JP2014513110A5 (https=)
JP2010523681A5 (https=)
EP2620432A3 (en) Diarylhydantoin compounds
JP2014503567A5 (https=)
JP2016506962A5 (https=)
JP2013542261A5 (https=)
JP2014526549A5 (https=)
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes